RxDoctor Payments Data

Jorge Reiley, MD

Neurology · Center Moriches, NYNPI 1053487058

Payments from drug & device makers

$4,105in general payments, 2019–2025

Across 158 payments — averaging $25.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$551
  • Neurocrine Biosciences, Inc.$352
  • Sunovion Pharmaceuticals Inc.$321
  • Lundbeck LLC$283
  • Biogen$274
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,105100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,105 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$303,175
Medicare patients
367
Services billed
5,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$104,547
Pramipexole ErPramipexole Di-Hcl13$9,591
Carbidopa-LevodopaCarbidopa/Levodopa161$2,400
Gabapentin207$1,897
Donepezil Hcl230$1,690
Memantine Hcl56$988
Galantamine ErGalantamine Hbr13$969
Carbidopa-Levodopa ErCarbidopa/Levodopa23$687
Pregabalin43$673
Phenytoin Sodium Extended21$502
Pyridostigmine Bromide11$392
Topiramate19$365
Levetiracetam27$356
Divalproex Sodium15$320
Escitalopram Oxalate87$317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$118$104,54712 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$110$39211 claims
Upsher-smith Laboratories LLCTopiramate$110$36519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,623 neurology providers in New York.

Other neurology in Center Moriches

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →